Tevogen Bio Holdings Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
TVGN$5.72-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets, December 31, 2025 and 2024
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash | $552,372 | $1,282,995 |
| Prepaid expenses and other assets | 828,592 | 919,088 |
| Due from related party | 158,819 | 158,819 |
| Total current assets | 1,539,783 | 2,360,902 |
| Property and equipment, net | 170,308 | 296,442 |
| Right-of-use assets - operating leases | 1,423,473 | 228,490 |
| Deferred transaction costs | 183,546 | - |
| Other assets | 1,065,884 | 575,841 |
| Total assets | $4,382,994 | $3,461,675 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $3,340,127 | $5,200,245 |
| Accrued expenses and other liabilities | 1,499,624 | 1,712,396 |
| Operating lease liabilities | 327,740 | 229,063 |
| Notes payable | 1,651,000 | 1,651,000 |
| Due to related party | 250,000 | 250,000 |
| Total current liabilities | 7,068,491 | 9,042,704 |
| Loan agreement | 4,400,000 | 1,000,000 |
| Operating lease liabilities | 1,122,750 | 5,796 |
| Derivative warrant liabilities | 26,479 | 87,180 |
| Total liabilities | 12,617,720 | 10,135,680 |
| Stockholders’ deficit | ||
| Series A Preferred Stock, $0.0001 par value; 2,000 shares authorized; 500 shares issued and outstanding as of December 31, 2025 and December 31, 2024 (liquidation value of $2,176,712 and December 31, 2025) | 2,799,990 | 2,799,990 |
| Series C Preferred Stock, $0.0001 par value; 1,300 shares authorized; 600 shares issued and outstanding as of December 31, 2025 and December 31, 2024 (liquidation value of $6,532,603 at December 31, 2025) | 6,000,000 | 6,000,000 |
| Common stock, $0.0001 par value; 800,000,000 shares authorized; 4,020,746 and 3,559,827 shares issued and outstanding at December 31, 2025 | 402 | 356 |
| Additional paid-in capital | 122,625,431 | 97,910,766 |
| Accumulated deficit | (139,660,549) | (113,385,117) |
| Total stockholders’ deficit | (8,234,726) | (6,674,005) |
| Total liabilities and stockholders’ deficit | $4,382,994 | $3,461,675 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.